Susan Casey Bleasdale | Medical Director Infection Prevention & Control and Antimicrobial Stewardship
University of Illinois Hospital & Health Sciences System

Susan Casey Bleasdale, Medical Director Infection Prevention & Control and Antimicrobial Stewardship, University of Illinois Hospital & Health Sciences System

Dr. Bleasdale is the physician lead for antimicrobial stewardship and infection prevention at the University of Illinois Hospital and Health Sciences System (UIH) and is a leader in related research.  In administrative roles, she directs initiatives to reduce HAIs, infections with multidrug resistant organisms (MDROs), and improve antimicrobial prescribing.  In research, she was the lead investigator for one of the first studies of chlorhexidine gluconate (CHG) use to reduce blood stream infections in intensive care unit patients.  Current research activity is related to the epidemiology of HAIs and MDROs, the study of interventions to reduce HAIs and improve antibiotic stewardship, and antimicrobial clinical trials.  Dr. Bleasdale is one of the investigators on the UIC Epicenter for the Prevention of Healthcare Associated Infections (HAIs).  This work studies of the transmission of HAIs via healthcare workers and the effective use of personal protective equipment to prevent transmission.  In addition, she is currently working on inpatient and ambulatory antimicrobial stewardship interventions. Her clinical practice is general infectious disease and HIV care.

She has activities related to infectious disease policy and guidelines through her role on the SHEA Guideline Committee, and as a member of the Infectious Disease Society of America (IDSA) Clinical Innovations Committee, and chair of the IDSA Antimicrobial Stewardship Centers of Excellence Selection Committee.

Appearances:



World Anti-Microbial Resistance Congress USA 2018 - Day 1 @ 15:30

The implications of antimicrobial resistance at the clinic and the bedside

  • History of resistance with patient perspectives
  • What we have been able to accomplish through stewardship and increased support for drug development of new antimicrobials
  • What resources are needed to further decrease the development of resistance and spread of current MDROs
last published: 16/Oct/18 16:45 GMT

back to speakers